ct-388
Peptideexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2021 (NCT04838405)
Timeline
Indications
Mechanism of action
GIP agonist
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06628362 | Phase 2 | Oct 30, 2024 | Carmot Therapeutics, Inc., Roche |
| NCT06525935 | Phase 2 | Aug 16, 2024 | Carmot Therapeutics, Inc., Roche |
| NCT04838405 | Phase 1 | Apr 1, 2021 | Carmot Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Carmot Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2021 |
| Roche | For profit | 2 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1